Veeva Systems Inc - Class A risk profile
30 Normal where most of the sector sits
Measured 21 October 2026 from VEEV's filed statements. Recomputed nightly.
30 (Normal), driven by Concentration at 58, over 6 weighted categories on the SOFTWARE profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 28 | Normal | Stable | One-year price volatility — 43.5% |
| Operating pressure | 23 | Normal | Stable | Costs outgrowing revenue — -5.4 percentage points |
| Cash conversion | 15 | Contained | Stable | Cash conversion — 1.56x |
| Leverage and coverage | 0 | Contained | Stable | Current ratio — 4.89x |
| Competitive position | 25 | Normal | Stable | Revenue-growth gap against peers — +18.8 percentage points |
| Concentration | 58 | Elevated | Stable | Geographic concentration — 4,490 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Veeva Systems Inc - Class A